HRMY - Harmony Biosciences Holdings Inc. (HRMY) Q4 2023 Earnings Call Transcript
2024-02-22 13:32:10 ET
Harmony Biosciences Holdings, Inc. (HRMY)
Q4 2023 Results Conference Call
February 22, 2024 08:30 AM ET
Company Participants
Luis Sanay - Head of Investor Relations
Jeffrey Dayno - President and CEO
Jeffrey Dierks - Chief Commercial Officer
Kumar Budur - Chief Medical Officer
Sandip Kapadia - Chief Financial Officer and Chief Administrative Officer
Conference Call Participants
Ami Fadia - Needham & Company
Charles Duncan - Cantor Fitzgerald
Francois Brisebois - Oppenheimer
David Amsellem - Piper Sandler
Danielle Brill - Raymond James
Presentation
Operator
Good morning. My name is Brittany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Fourth Quarter and Full Year 2023 Financial Results Conference call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session [Operator Instructions]. Please be advised that today's conference may be recorded [Operator Instructions].
I would now like to turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.
Luis Sanay
Thank you, operator. Good morning, everyone. And thank you for joining us today as we review Harmony Biosciences fourth quarter and full year 2023 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our Web site to find the materials that accompany our discussion today, including the reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer. As a reminder, we will be making forward looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially and we undertake no obligation to update these statements, even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. ...
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript